IL-6 trans-signaling is a plausible inflammaging axis, but not a universal longevity bottleneck
fact lesson principle aging immunology
IL-6 trans-signaling is a plausible inflammaging axis, but not a universal longevity bottleneck
''结论'': IL-6 trans-signaling is biologically important and druggable, but the current public evidence still falls short of a universal longevity bottleneck.
''Key evidence'':
# Nature Reviews Immunology 2023 (Targeting IL-6 trans-signalling: past, present and future prospects) states that selective blockade of IL-6 trans-signaling (e.g. sgp130 / sgp130Fc / olamkicept-like approaches) has therapeutic potential across inflammatory diseases.
# A 2025 Gastro Hep Advances paper (PMCID PMC12681722) reports that blockade of IL-6 trans-signaling in mice can induce mature-onset obesity in the presence of certain gut microbiota, showing that the axis can be context-dependent and even harmful in a specific aging/metabolic context.
''筛选教训'':
# 如果一个候选主要依赖 disease-model readouts、缺乏直接 lifespan/healthspan 证据，而且存在明显 microbiota/context sensitivity，就不应把它快速升级为“通用长寿瓶颈”。
# IL-6 family 仍值得保留为机制候选，但优先级应低于已经具备直接 lifespan 终点的节点（例如 IL-11）。